Larry Egan

Professor MB BCH BAO MRCPI MD

Contact Details

Professor
Dept of Pharmacology
Clinical Sciences Institute
Nui Galway

T: Ext. 5355
E: laurence.egan@nuigalway.ie
 
researcher

Biography

Peer Reviewed Journals

  Year Publication
'Thromboxane A2 and prostacyclin receptors exert opposing effects on the severity of experimental murine colitis'
Egan, L. J., Smith, J. R., Truong, F., Kirstein, S., Sugimoto, Y., Narumiya, S., Varki, N. M., Insel, P. A., Kagnoff, M. F. & Eckmann, L. 'Thromboxane A2 and prostacyclin receptors exert opposing effects on the severity of experimental murine colitis'. [Details]
(2011) 'Autophagosomal I kappa B alpha Degradation Plays a Role in the Long Term Control of Tumor Necrosis Factor-alpha-induced Nuclear Factor-kappa B (NF-kappa B) Activity'
Colleran, A,Ryan, A,O'Gorman, A,Mureau, C,Liptrot, C,Dockery, P,Fearnhead, H,Egan, LJ (2011) 'Autophagosomal I kappa B alpha Degradation Plays a Role in the Long Term Control of Tumor Necrosis Factor-alpha-induced Nuclear Factor-kappa B (NF-kappa B) Activity'. Journal Of Biological Chemistry, 286 :22886-22893 [DOI] [Details]
(2011) 'Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease'
Ali, RAR,Dooley, C,Comber, H,Newell, J,Egan, LJ (2011) 'Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease'. Clinical Gastroenterology And Hepatology, 9 :584-104 [DOI] [Details]
(2011) 'Mechanisms of Drug Toxicity or Intolerance'
Egan, LJ (2011) 'Mechanisms of Drug Toxicity or Intolerance'. Digestive Diseases, 29 :172-176 [DOI] [Details]
(2011) 'Autophagosomal IkBa degradation plays a role in the long term control of tumor necrosis factor-a-induced NF-kB activation'
Colleran A, O'Gorman A, Ryan A, Mureau C, Liptrot C, Dockery P, Fearnhead H, Egan L. (2011) 'Autophagosomal IkBa degradation plays a role in the long term control of tumor necrosis factor-a-induced NF-kB activation'. Journal of Biological Chemistry, 286 :22886-22893 [DOI] [Details]
(2010) 'The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival'
Rahman MK, Midtling EH, Svingen PA, Xiong Y, Bell MP, Tung J, Smyrk T, Egan LJ, Faubion WA Jr. (2010) 'The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival'. J. Immunol, 184 (12):7247-7256 [Details]
(2010) 'Regulation of NF-kappa B responses by epigenetic suppression of I kappa B alpha expression in HCT116 intestinal epithelial cells'
O'Gorman, A,Colleran, A,Ryan, A,Mann, J,Egan, LJ (2010) 'Regulation of NF-kappa B responses by epigenetic suppression of I kappa B alpha expression in HCT116 intestinal epithelial cells'. American Journal Of Physiology-Gastrointestinal And Liver Physiology, 299 :96-105 [DOI] [Details]
(2010) 'Upregulation of DNA Methyltransferase-Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6'
Foran, E,Garrity-Park, MM,Mureau, C,Newell, J,Smyrk, TC,Limburg, PJ,Egan, LJ (2010) 'Upregulation of DNA Methyltransferase-Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6'. Molecular Cancer Research, 8 :471-481 [DOI] [Details]
(2010) 'Upregulation of DNA methyltransferase-mediated gene silencing, anchorage independent growth and migration of colon cancer cells by interleukin-6'
Foran E, Garrity-Park M., Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ. (2010) 'Upregulation of DNA methyltransferase-mediated gene silencing, anchorage independent growth and migration of colon cancer cells by interleukin-6'. Molecular Cancer Research, 8 (4):471-481 [Details]
(2009) 'Is there a role for NF?B in TRAIL resistance. Ann N.Y'
Plantivaux A, Szegezdi E, Samali A, Egan L. (2009) 'Is there a role for NF?B in TRAIL resistance. Ann N.Y'. Academy Sci, 1171 :38-49 [Details]
(2009) 'Inhibition of NF-?B in colon cancer significantly decreases tumour burden and increases survival time in a mouse model of peritoneal metastasis'
Ryan A, Colleran A, O'Gorman A, Foran E, Egan LJ. (2009) 'Inhibition of NF-?B in colon cancer significantly decreases tumour burden and increases survival time in a mouse model of peritoneal metastasis'. Poster Presentation, DDW, Chicago, [Details]
(2008) 'Inhibition of NF-?B in colon cancer cells significantly decreases tumour burden and increases host survival time in a mouse model of peritoneal metastasis'
Ryan A, Colleran A, O'Gorman A, Foran E, Egan LJ. (2008) 'Inhibition of NF-?B in colon cancer cells significantly decreases tumour burden and increases host survival time in a mouse model of peritoneal metastasis'. Presented at Keystone Symposia, Banff, CA, [Details]
(2008) 'Microenvironment to nucleus signaling: Interleukin-6 decreases tumor suppressor gene expression in HCT116 cells through DNMT1-mediated epigenetic silencing'
Foran E, Egan LJ. (2008) 'Microenvironment to nucleus signaling: Interleukin-6 decreases tumor suppressor gene expression in HCT116 cells through DNMT1-mediated epigenetic silencing'. Presented at Keystone Symposia, Banff, CA, [Details]
(2008) 'Longterm suppression of I?Ba by inflammatory cytokines:'
Colleran A, Ryan A, Egan LJ. (2008) 'Longterm suppression of I?Ba by inflammatory cytokines:'. Molecular Mechanisms. Presented at Keystone Symposia, Banff, CA, [Details]
(2008) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'
Toruner, M,Loftus, EV,Harmsen, WS,Zinsmeister, AR,Orenstein, R,Sandborn, WJ,Colombel, JF,Egan, LJ (2008) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'. Gastroenterology, 134 :929-936 [DOI] [Details]
(2008) 'Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial'
Solem, CA,Loftus, EV,Fletcher, JG,Baron, TH,Gostout, CJ,Petersen, BT,Tremaine, WJ,Egan, LJ,Faubion, WA,Schroeder, KW,Pardi, DS,Hanson, KA,Jewell, DA,Barlow, JM,Fidler, JL,Huprich, JE,Johnson, CD,Harmsen, WS,Zinsmeister, AR,Sandborn, WJ (2008) 'Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial'. Gastrointest Endosc, 68 :255-266 [DOI] [Details]
(2008) 'Inflammatory Bowel Diseases'
Egan LJ. Maaser C. (2008) 'Inflammatory Bowel Diseases'. Pharmacology and Therapeutics, Principles to Practice, 33 :487-503 [Details]
(2008) 'Inflammation and Immunomodulation'
Egan LJ. (2008) 'Inflammation and Immunomodulation'. Pharmacology and Therapeutics, Principles to Practice, 11 :157-172 [Details]
(2008) 'I?Ba as a target for epigenetic silencing in colon cancer'
O'Gorman A, Ryan A, Foran E, Mureau C, Egan LJ. (2008) 'I?Ba as a target for epigenetic silencing in colon cancer'. Presented at Keystone Symposia, Banff CA, [Details]
(2007) 'Gastroesophageal reflux disease in pregnancy'
Ali, RAR,Egan, LJ (2007) 'Gastroesophageal reflux disease in pregnancy'. Best Practice & Research In Clinical Gastroenterology, 21 :793-806 [DOI] [Details]
(2007) 'Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2'
Kang-Decker N, Cao S, Chatteriee S, Yao J, Egan LJ, Semela D, Mukhopadhyay D, Shah V. (2007) 'Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2'. Journal of Cellular Science, 1 (120(Pt 3)):492-501 [Details]
(2007) 'A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain'
Egan LJ. (2007) 'A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain'. Clinical gastroenterology and Hepatology, 5 (2):170-171 [Details]
(2007) 'Allopurinol and 6MP: Steering through the therapeutic obstacle course'
Egan LJ. (2007) 'Allopurinol and 6MP: Steering through the therapeutic obstacle course'. Inflammatory Bowel Disease, 13 (10):1312-1313 [DOI] [Details]
(2006) 'The AmpliChip CYP450 test: Principles, challenges, and future clinical utility in digestive disease'
Juran, BD,Egan, LJ,Lazaridis, KN (2006) 'The AmpliChip CYP450 test: Principles, challenges, and future clinical utility in digestive disease'. Clinical Gastroenterology And Hepatology, 4 :822-830 [DOI] [Details]
(2006) 'Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1'
Toruner, M,Fernandez-Zapico, M,Sha, JJ,Pham, L,Urrutia, R,Egan, LJ (2006) 'Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1'. Journal Of Biological Chemistry, 281 :8686-8696 [DOI] [Details]
(2006) 'Pharmacogenomics in inflammatory bowel disease'
Egan, LJ,Derijks, LJJ,Hommes, DW (2006) 'Pharmacogenomics in inflammatory bowel disease'. Clinical Gastroenterology And Hepatology, 4 :21-28 [DOI] [Details]
(2006) 'Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice'
Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. (2006) 'Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice'. Inflammatory Bowel Disease, 12 (1):29-32 [Details]
(2005) 'Positioning novel biologic, probiotic, and apheresis therapies for Chron's disease and ulcerative colitis'
Egan, L. J. and Sandborn, W. J. (2005) 'Positioning novel biologic, probiotic, and apheresis therapies for Chron's disease and ulcerative colitis'. Current Gastroenterology Reports, 7 (6):485-491 [Details]
(2005) 'Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines'
Thomas, C., Myhre, G. M., Tschumper, R., Sreekumar, R., Jelinek, D., McKean, D. J., Sandborn, W. J., Lipsky, J. J. & Egan, L. J. (2005) 'Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines'. Journal of Pharmacology and Experimental Therapeutics, 312 (2):537-545 [Details]
(2005) 'Acute pancreatitis in Crohn's disease: clinical features and outcomes'
Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ (2005) 'Acute pancreatitis in Crohn's disease: clinical features and outcomes'. Inflammatory Bowel Diseases, 11 (12):1080-1084 [Details]
(2005) 'Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease'
Toruner M, Harewood GC, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ (2005) 'Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease'. Inflammatory Bowel Diseases, 11 (5):428-434 [Details]
(2004) 'IKK -dependent NF- B activation provides radioprotection to the intestinal epithelium'
Egan, L. J., Eckmann, L., Greten, F., Chae, S., Li, Z-W., Myhre, G. M., Robine, S., Karin, M. & Kagnoff, M. F. (2004) 'IKK -dependent NF- B activation provides radioprotection to the intestinal epithelium'. Proceedings of the National Academy of Sciences USA, 101 :2452-2457 [Details]
(2004) 'Expression of EBI3 and related molecules by human intestinal epithelium'
Maaser, C., Egan, L. J., Birkenbach, M. P., Eckmann, L. & Kagnoff, M. F. (2004) 'Expression of EBI3 and related molecules by human intestinal epithelium'. Immunology, 112 (Issue no 3):437-445 [Details]
(2004) 'IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer'
Greten, F. R., Eckmann, L., Greten, T. F., Park, J-M., Li, Z-W., Egan, L. J., Kagnoff, M. F. & Karin, M. (2004) 'IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer'. Cell, 118 :285-296 [Details]
(2004) 'Cyclosporine, Tacrolimus and Mycophenolate Mofetil in the treatment of inflammatory bowel disease'
Loftus, C. G., Egan, L. J. & Sandborn, W. J. (2004) 'Cyclosporine, Tacrolimus and Mycophenolate Mofetil in the treatment of inflammatory bowel disease'. Gastroenterology Clinics of North America, 33 (2):141-169 [Details]
(2004) 'The safety profile of Infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients'
Colombel, J-F., Loftus, E. V. Jr, Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R. & Sandborn, W. J. (2004) 'The safety profile of Infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients'. Gastroenterology, 126 (1):19-31 [Details]
(2004) 'Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution'
Myhre, G. M., Toruner, M., Abraham, S. & Egan, L. J. (2004) 'Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution'. American Journal of Physiology: Gastrointestinal and Liver Physiology, 10 [Details]
(2004) 'Drug interactions in gastroenterology: mechanisms, consequences and how to avoid'
Egan, L. J. (2004) 'Drug interactions in gastroenterology: mechanisms, consequences and how to avoid'. Clinical Gastroenterology and Hepatology, 2 (9):725-730 [Details]
(2004) 'Advances in the treatment of Crohn's disease'
Egan, L. J. & Sandborn, W. M. (2004) 'Advances in the treatment of Crohn's disease'. Gastroenterology, 126 (6):1574-1581 [Details]
(2003) 'Nuclear factor B activation promotes restitution of wounded intestinal epithelial monolayers'
Egan, L. J., De Lecea, A., Lehrman, E. D., Myhre, G. M., Eckmann, L. & Kagnoff, M. F. (2003) 'Nuclear factor B activation promotes restitution of wounded intestinal epithelial monolayers'. American Journal of Physiology: Cell Physiology, 285 (5):C1028-C1035 [Details]
(2003) 'The two faces of IKK and NF- B inhibition, prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion'
Chen, L-W., Egan, L. J., Li, Z-W., Kagnoff, M. F. & Karin, M. (2003) 'The two faces of IKK and NF- B inhibition, prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion'. Nature Medicine, 9 (5):575-581 [Details]
(2003) 'CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-esophageal reflux disease: variant alleles predict gastric acid suppression, but not esophageal acid exposure or reflux symptoms'
Egan, L. J., Myhre, G. M., Mays, D. C., Dierkhising, R. A., Kammer, P. P. & Murray, J. A. (2003) 'CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-esophageal reflux disease: variant alleles predict gastric acid suppression, but not esophageal acid exposure or reflux symptoms'. Alimentary Pharmacology & Therapeutics, 172 (12):1521-1528 [Details]
(2002) 'Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF- B and MAP kinase pathways and the upregulated expression of interleukin-8'
Berin, M. C., Darfeuille-Michaud, A., Egan, L. J., Miyamoto, Y. & Kagnoff, M. F. (2002) 'Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF- B and MAP kinase pathways and the upregulated expression of interleukin-8'. Cellular Microbiology, 4 :635-647 [Details]
(2000) 'Endoscopic removal of an embedded biliary Wallstent by piecemeal extraction'
Egan, L. J. & Baron, T. H. (2000) 'Endoscopic removal of an embedded biliary Wallstent by piecemeal extraction'. Endoscopy, 32 :492-494 [Details]
(2000) 'Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate in treatment resistant inflammatory bowel diseas'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (2000) 'Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate in treatment resistant inflammatory bowel diseas'. Inflammatory Bowel Diseases, 6 :286-289 [Details]
(2000) 'New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors'
Egan, L. J. & Murray, J. A. (2000) 'New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors'. Digestive Diseases, 18 :58-63 [Details]
(1999) 'The intestinal and systemic pharmacokinetics of methotrexate in inflammatory bowel disease patients'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'The intestinal and systemic pharmacokinetics of methotrexate in inflammatory bowel disease patients'. Clinical Pharmacology & Therapeutics, 65 :29-39 [Details]
(1999) 'Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate'. Inflammatory Bowel Diseases, 5 :167-173 [Details]
(1999) 'A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis'
Egan, L. J., Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Mays, D. C., Pike, M. G., Zinsmeister, A. R. & Lipsky, J. J. (1999) 'A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis'. Alimentary Pharmacology & Therapeutics, 13 :1597-1604 [Details]
(1999) 'Inhibition of interleukin-1-stimulated NF- B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'Inhibition of interleukin-1-stimulated NF- B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity'. Journal of Biological Chemistry, 274 :26448-26453 [Details]
(1998) 'Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1998) 'Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision'. Alimentary Pharmacology and Therapeutics, 12 :679-684 [Details]
(1998) 'Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine'
Egan, L. J, Sandborn, W. J. & Tremaine, W. J. (1998) 'Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine'. American Journal of Gastroenterology, 93 :442-448 [Details]
(1998) 'Herpetic whitlow of the toe: an unusual manifestation of infection with Herpes Simplex virus type 2'
Egan, L. J., Bylander, J. M., Agerter, D. C. & Edson, R. S. (1998) 'Herpetic whitlow of the toe: an unusual manifestation of infection with Herpes Simplex virus type 2'. Clinical Infectious Diseases, 26 :196-197 [Details]
(1996) 'Methotrexate for inflammatory bowel disease: pharmacology and preliminary results'
Egan L. J. & Sandborn W. J. (1996) 'Methotrexate for inflammatory bowel disease: pharmacology and preliminary results'. Mayo Clinic Proceedings, 71 (1):69-80 [Details]
(1995) 'Enteropathy associated T cell lymphoma; Low frequency of Epstein Barr virus in these tumors'
Walsh, S. V., Egan, L. J., Connolly, C. E., Egan, E. L., Stevens, F. M. & McCarthy, C. F. (1995) 'Enteropathy associated T cell lymphoma; Low frequency of Epstein Barr virus in these tumors'. Modern Pathology, 8 (7) [Details]
(1995) 'Celiac associated lymphoma a single institution experience of 30 cases in the combination chemotherapy era'
Egan, L. J., Walsh, S. V., Stevens, F. M., Connolly, C. E., Egan, E. L. & McCarthy, C. F. (1995) 'Celiac associated lymphoma a single institution experience of 30 cases in the combination chemotherapy era'. Journal of Clinical Gastroenterology, 21 (2):123-129 [Details]
(1995) 'CELIAC-ASSOCIATED LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE OF 30 CASES IN THE COMBINATION CHEMOTHERAPY ERA'
EGAN, LJ,WALSH, SV,STEVENS, FM,CONNOLLY, CE,EGAN, EL,MCCARTHY, CF (1995) 'CELIAC-ASSOCIATED LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE OF 30 CASES IN THE COMBINATION CHEMOTHERAPY ERA'. Journal Of Clinical Gastroenterology, 21 :123-129 [Details]
(1995) 'ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS'
WALSH, SV,EGAN, LJ,CONNOLLY, CE,STEVENS, FM,EGAN, EL,MCCARTHY, CF (1995) 'ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS'. Modern Pathology, 8 :753-757 [Details]
(1994) 'HEREDITARY-DEFICIENCY OF THE 7TH COMPONENT OF COMPLEMENT AND RECURRENT MENINGOCOCCAL INFECTION - INVESTIGATIONS OF AN IRISH FAMILY USING A NOVEL HEMOLYTIC SCREENING ASSAY FOR COMPLEMENT ACTIVITY AND C7 M/N ALLOTYPING'
EGAN, LJ,ORREN, A,DOHERTY, J,WURZNER, R,MCCARTHY, CF (1994) 'HEREDITARY-DEFICIENCY OF THE 7TH COMPONENT OF COMPLEMENT AND RECURRENT MENINGOCOCCAL INFECTION - INVESTIGATIONS OF AN IRISH FAMILY USING A NOVEL HEMOLYTIC SCREENING ASSAY FOR COMPLEMENT ACTIVITY AND C7 M/N ALLOTYPING'. Epidemiology And Infection, 113 :275-281 [Details]

Books

  Year Publication
(2008) Pharmacology and Therapeutics, Principals to Practice. Saunders, Philadelphia, 2008. Associate Editor.
Egan, L. (2008) Pharmacology and Therapeutics, Principals to Practice. Saunders, Philadelphia, 2008. Associate Editor. [Details]

Book Chapters

  Year Publication
'Ileoanal pouch: frequent evacuation'
Egan, L. J. & Phillips, S. F. 'Ileoanal pouch: frequent evacuation' In: Advanced Therapy in Gastroenterology and Liver Disease - 5. B.C. Decker, Hamilton. [Details]
'Mechanisms of action of drugs in IBD'
Egan, L. J. 'Mechanisms of action of drugs in IBD' In: Falk Symposium. [Details]
(2004) 'Tumor necrosis factor alpha'
Egan, L. J. (2004) 'Tumor necrosis factor alpha' In: Encyclopedia of Gastroenterology. In Johnson, L. R. Elsevier (USA). [Details]
(2003) 'Clinical pharmacology in inflammatory bowel disease: strategies to optimize current medical therapy'
Egan, L. J. & Sandborn, W. J. (2003) 'Clinical pharmacology in inflammatory bowel disease: strategies to optimize current medical therapy' In: Inflammatory Bowel Disease, From Bench to Bedside . Kluwer Academic Publishers. [Details]
(2001) 'Ileoanal pouch patient: evaluation of excessive bowel movements'
Egan, L. J. & Phillips, S. F. (2001) 'Ileoanal pouch patient: evaluation of excessive bowel movements' In: Advanced therapy of inflammatory bowel disease (2/e) IHamilton. [Details]
(1998) 'Drug therapy of Inflammatory Bowel Disease'
Egan, L. J. & Sandborn, W. J. (1998) 'Drug therapy of Inflammatory Bowel Disease' In: Drugs of Today. [Details]

Conference Publications

  Year Publication
(2008) APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS
Plantivaux A, Szegezdi E, Samali A, Egan LJ. (2008) TRAIL resistance in colon cancer cells: is NF-?B involved? APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS [Details]

Abstract

  Year Publication
(2010) Analysis of 6 circulating cytokines and colonic STAT3 activation pattern in patients with inflammatory bowel disease of different disease activity and duration.
Ali, RAR,Hartnett, L,Egan, LJ (2010) Analysis of 6 circulating cytokines and colonic STAT3 activation pattern in patients with inflammatory bowel disease of different disease activity and duration. Abstract [Details]

Conference Poster

  Year Publication
(1994) Lymphoma in celiac disease Improved outcome with intensive combination chemotherapy. World Congresses of Gastroenterology.
Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. (1994) Lymphoma in celiac disease Improved outcome with intensive combination chemotherapy. World Congresses of Gastroenterology. Conference Poster [Details]
(1994) Hereditary terminal complement deficiency and recurrent meningococcal infection.. National Scientific Medical Meeting. Irish Journal of Medical Science.
Egan LJ, Orren A, Doherty J, McCarthy CF. (1994) Hereditary terminal complement deficiency and recurrent meningococcal infection.. National Scientific Medical Meeting. Irish Journal of Medical Science. Conference Poster [Details]

Editorial

  Year Publication
(2007) A nudge in the right direction: Shaping the metabolic fate of thiopurines for therapeutic gain.
Egan, LJ (2007) A nudge in the right direction: Shaping the metabolic fate of thiopurines for therapeutic gain. Editorial [DOI] [Details]
(2007) Allopurinol and 6MP: Steering through the therapeutic obstacle course.
Egan, LJ (2007) Allopurinol and 6MP: Steering through the therapeutic obstacle course. Editorial [DOI] [Details]

Downloads